Saturday, September 02, 2023 11:34:58 PM
Why is it that none of the FUD spreaders will respond to this post that cites the real experts? I’m talking about Ex, Learning Curve, Poorman, Legend, etc…..
Have posted many times.
1) External Control Arms in Oncology: Current Use and Future Directions
Including external controls for primary evidence of efficacy requires careful pre-specification of study design elements.
LITERATURE OR SUMMARY LEVEL DATA
. Not appropriate for direct comparison as external control to establish safety or effectiveness
Careful planning in the design phase before study initiation along with the implementation of a detailed protocol can ensure comparability of patient populations and data, such that the planned statistical analyses that adjust for residual biases can be reasonably relied on for better estimation of treatment effect in isolation.
2) Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
Specific design elements to prespecify in the protocol (i.e., before conducting an externally controlled trial) include suitable study data sources,baseline eligibility (inclusion and exclusion) criteria,appropriate exposure definitions and windows, well-defined and clinically meaningful endpoints, cogent analytic plans, and approaches to minimize missing data and sources of bias
A specific design consideration for externally controlled trials involves prespecifying plans regarding how to measure and analyze data on important confounding factors and sources of bias
Plenty more concerns raised in those 2 sources (and others) straight from the FDA.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
